Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP3 | P08254 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10633511 | 0.82 | CASR (0.51) | KDM4EKMT2AKCNH2LMNAMAPK1 | |
| SCHEMBL1282522 | 0.82 | KCNA3 (0.55) | MMP1MMP3LMNA | |
| SCHEMBL10893152 | 0.80 | KCNA3 (0.53) | MMP1MMP3LMNA | |
| SCHEMBL8813381 | 0.77 | KDM4E (0.52) | KDM4EKMT2AKCNH2DRD2DRD4 | |
| SCHEMBL1281996 | 0.77 | MAPT (0.51) | KDM4EKMT2AMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL10202959 | 0.75 | KMT2A (0.56) | KDM4EKMT2AKCNH2DRD2DRD4 | |
| SCHEMBL8551026 | 0.75 | KMT2A (0.73) | KDM4EKMT2AKCNH2DRD2DRD4 | |
| SCHEMBL15178204 | 0.75 | KMT2A (0.52) | KDM4EKMT2AKCNH2DRD2DRD4 | |
| SCHEMBL9774806 | 0.74 | DRD2 (0.60) | KDM4EKMT2AKCNH2DRD2DRD4 | |
| SCHEMBL1283620 | 0.74 | KDM4E (0.56) | KDM4EKMT2AKCNH2HRH3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443098-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2012-04-25 | — | — | EP | disclosed |
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| WO-2010146112-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088660-A1 | Antifungal 1,2,4-triazolyl Derivatives | ERG28, CYP51A1, DPM1 | MMP1 3785/4885MMP3 2871/4885KDM4E 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.